Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

14.59
-0.2300-1.55%
Pre-market: 14.58-0.0100-0.07%04:38 EDT
Volume:4.86M
Turnover:72.03M
Market Cap:4.73B
PE:-26.74
High:15.02
Open:14.78
Low:14.56
Close:14.82
52wk High:15.02
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:0.83
T/O Rate:2.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:5.28
PE(LYR):-29.77

Loading ...

AbCellera Biologics call volume above normal and directionally bullish

TIPRANKS
·
Jul 10

Press Release: Abcellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Dow Jones
·
Jul 08

Abcellera Schedules Q2 2026 Results, Earnings Call

Reuters
·
Jul 08

Abcellera Biologics Raised to Buy from Hold by Benchmark

Dow Jones
·
Jul 07

Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $11

MT Newswires Live
·
Jul 07

Abcellera Biologics Inc : Benchmark Raises to Buy from Hold

THOMSON REUTERS
·
Jul 07

What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders

Simply Wall St.
·
Jul 07

Abcellera Files Form 3 as Director Lynn Seely Reports no Beneficial Ownership

Reuters
·
Jul 07

AbCellera Biologics Adds Independent Director to Board

TIPRANKS
·
Jul 07

AbCellera apponts Lynn Seely to board of directors

TIPRANKS
·
Jul 06

Abcellera Appoints Lyell CEO Lynn Seely to Board as Independent Director

Reuters
·
Jul 06

Abcellera Appoints DR. Lynn Seely to Its Board of Directors

THOMSON REUTERS
·
Jul 06

Is AbCellera (ABCL) Using the Jazz Partnership to Quietly Redefine Its Oncology Platform Strategy?

Simply Wall St.
·
Jun 28

AbCellera Biologics call volume above normal and directionally bullish

TIPRANKS
·
Jun 25

Why AbCellera Biologics (ABCL) Is Up 5.5% After New Jazz T-Cell Engager Collaboration Agreement

Simply Wall St.
·
Jun 20

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)

TIPRANKS
·
Jun 18

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Reuters
·
Jun 17

Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact

Dow Jones
·
Jun 17

Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies

TIPRANKS
·
Jun 17

Jazz Pharmaceuticals, AbCellera team up on T-cell engaging multispecific antibodies for GI cancers

Reuters
·
Jun 17